2024-04-20 04:06:30
20 April 2024 Today at 06:00
The Liège biotechnology company PDC*line registered good intermediate clinical results with its therapeutic vaccine once morest lung cancer.
Encouraging new clinics for Liège biotechnology PDC*line Pharma, specialized in immuno-oncology: its therapeutic vaccine candidate, intended for the treatment of lung cancer, has achieved initial positive results in a human study.
Called PDC-lunge-01, this product candidate is a therapeutic vaccine once morest “non-small cell” lung cancer (NSCLC), the most common lung cancer (80% of cases). Unlike traditional vaccines, which prevent disease, therapeutic vaccines are designed to treat cancer that is already present and reduce its potential growth. PDC*line primarily targets cancer in already advanced stages, metastasized and inoperable, in combination with existing anti-cancer treatment.
also read
Cell and gene therapies, exosomes, phages: the new revolution in medicine
The clinical phase I/II study has been carried out at 17 clinical sites in France, Belgium, Germany, the Netherlands and Poland, with 67 patients, as monotherapy or in combination with Keytruda from Merck, reference first-line treatment.
Preliminary data presented at the American Association for Cancer Research (AACR) annual meeting show that the high-dose vaccine, combined with Keytruda, generates immunological activity in a majority of patients and a promising antitumor response in NSCLC, with a moderate safety profile. The final analysis of the clinical trial will be performed in the third quarter of 2024.
“We were selected for an oral presentation at the AACR in San Diego, along with other companies such as BioNTech.”
Eric Halioua
Co-founder and CEO of PDC*line Pharma.
“In the current state of what’s been published, these are very good results. And that’s why“We were selected for an oral presentation at the AACR in San Diego, along with other companies such as BioNTech.”, pleases CEO and co-founder of the company, Eric Halioua. But you must always be on your guard, because you are obviously very good as long as there are no others who are better than you. Next, we need to confirm the intermediate data, because what we presented is 19 of the 45 patients. Finally, we are still in phase I/II, so it is the next study, a randomized phase II, that will be important, he continues.
Very good safety data in the clinical study PDC*line
This next clinical trial will begin in the second quarter of 2025 and include approximately 200 patients, according to the CEO. Currently, PDC*line is the only company working on a first-line therapeutic vaccine once morest lung cancer. On the other hand, there are other approaches based on different therapeutic modalities that are in clinical development, such as those called “anti-Tigit”.
Something that doesn’t worry Eric Halioua. “Lung cancer is so common that there is room. In addition – if we confirm our results – we have the advantage of having very good safety data in our clinical study. This is not the case for others, which often have significant side effects. The more exogenous products you add, the more toxicities you will have that will accumulate. In vaccine approaches, it is the immune system itself that is stimulated, which will break down and eat the tumor. The safety of cancer vaccines is very good. We also see that in the health field there is considerable dynamism around vaccines once morest cancer.
PDC*line is the only company working on a first-line therapeutic vaccine once morest lung cancer.
Liège biotech, which has established itself at LégiaPark and has 44 employees, is itself working on a second therapeutic vaccine project, targeting colon cancer. This is an initiative that is part of the Innovation Partnership for Innovative Therapies which the region of Wallonia launched a few months ago. PDC*line Pharma teamed up in this project with the Walloon sequencing and biopsy specialist, OncoDNA, the technology company salamanderU and the research institutes UCLouvain-IREC and ULB-BCTL.
“The lung vaccine is a ready-to-use vaccine. The one once morest colon cancer is personalized medicine.”, further specifies Eric Halioua. “We’re going to look for specific mutations in the patient’s tumor that will be much more immunogenic than general mutations. This means taking the tumor, sequencing it and identifying the immunogenic peptides, and then synthesizing them to make a personalized vaccine. It’s clear that these become much more complex and expensive. There really has to be an extremely attractive benefit to justify the prices of these products.”
The summary
- The Liège biotechnology company PDC*line Pharma registered good preliminary clinical results with its therapeutic vaccine once morest lung cancer.
- If these results are confirmed, a new one clinical study expected to start in the second quarter of 2025.
- Pour l’instant, PDC*line is the only company working on a therapeutic vaccine on the front line once morest lung cancer.
- The Liège biotechnology is working on a second therapeutic vaccine project, targeting colon cancer.
1713588381
#PDCline #therapeutic #vaccine #overcomes #hurdle
